CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 76 enrolled
Drug / intervention
NovoSevendrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03251547
NCT03251547N/ACompleted
CompareCT.gov

Recombinant Activated Factor VII (rFVIIa/ NovoSeven®) in the Management of Massive Bleeding in Hospital Universiti Sains Malaysia

Universiti Sains Malaysia·observational·Posted Aug 16, 2017·Updated Oct 10, 2018

In Brief

An observational study evaluating NovoSeven for Massive Hemorrhage and 2 related conditions. Completed, enrolled 76 participants across 1 site.

Detailed Summary

This is a retrospective descriptive study, to study the treatment indications, changes in transfusion need, coagulation profiles changes and clinical outcome (survival, complication) of non-haemophiliac patients who received activated factor seven (rFVIIa / NovoSeven®) during massive bleeding in Hospital Universiti Sains Malaysia (HUSM)

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsMassive Hemorrhage, Massive Blood Loss, Massive Blood Transfusion; Thrombocytopenia
CountriesMalaysia
Collaborators--

Timeline

N/ACompletedFinished
201820192020202120222023202420252026
First PostedAug 16, 2017
Enrollment StartAug 21, 2017
Primary CompletionOct 15, 2017
Study CompletionNov 15, 2017
TodayJul 2, 2026
Enrollment to primary: 2 monthsPosted 8.9 years ago

Interventions

NovoSevendrug

To survey retrospectively the treatment indications, clinical outcome, transfusion need and changes in coagulation profiles of non-haemophiliac patients who had received rFVIIa during massive bleeding